Canaccord’s John Newman now sees almost 18% in upside potential for SAGE following a big clinical home run in major depressive disorder.
Experienced investors in search of growth know to look beyond current trends and market momentum or rely on pundit’s expectations. Today’s results are …
Brexanolone poised to become first approved therapy for PPD, says Needham’s Danielle Brill.
